Home Reported Outcomes in C3G Study
ConditionC3 Glomerulopathy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorNovartis Pharmaceuticals
About this trial
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall Health-related Quality of Life (HRQoL) experienced by C3 glomerulopathy (C3G) patients and their caregivers. By primarily utilizing home reported outcomes (HRO) data on symptom burden and treatment usage, supplemented with patient-reported outcome (PRO) measures (collected at baseline and monthly), the study seeks to establish a new real-world data (RWD) source to understand symptom variability and HRQoL as reported by C3G patients and caregivers, including those taking iptacopan
Eligibility criteria
Qualifiers
Clinical diagnosis of C3G, regardless of symptom, treatment, or transplant history
Adult aged 18 or older; adult caregiver to an adult patient aged 18 or older; or adult caregiver to a pediatric patient under 18 years of age
Able to provide informed consent
Has access to technology (i.e. mobile phone, tablet) that facilitates their participation in the app-based study
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
100 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov